Irish Physician Professor Patrick Treacy Receives International Regenerative Medicine Innovation Award in New Delhi
Irish physician and scientist Professor
Patrick Treacy has received an international innovation award at the 11th IASRM
World Congress – Longevity Revolution 2026 in New Delhi, recognising his
pioneering contributions to regenerative medicine, including platelet-rich
plasma, stem-cell approaches and photo biomodulation.
Treacy has an academic background spanning
both medicine and basic science. He graduated in medicine from the Royal
College of Surgeons in Ireland (RCSI) and holds an honours degree in Biochemistry
from Queen’s University Belfast (QUB), a combination that has influenced
his longstanding interest in translating cellular biology and biochemical
signalling into clinical regenerative medicine.
His work has included the early clinical
application of platelet-rich plasma (PRP) and platelet-derived growth
factors, stem-cell and regenerative approaches, and red-light photo
biomodulation (PBM) for tissue repair, skin rejuvenation and hair
restoration. More recently, this work has extended into cellular signalling,
inflammation, mitochondrial function and the biological pathways associated
with ageing.
The New Delhi recognition follows the World
Regenerative Medicine Innovation Award, presented to Treacy at the World
Scientific Conference at King’s College, Cambridge, in August 2025. That
award recognised his contributions to non-surgical hair restoration and the
treatment of burns and vascular occlusions using regenerative therapies
involving PRP, stem-cell approaches and photobiomodulation.
At the 2026 IASRM World Congress, Treacy
delivered a keynote address entitled “Pathways of Ageing and Human
Longevity,” examining genomic, epigenetic, mitochondrial, inflammatory and
regenerative mechanisms involved in biological ageing.
His presentation also emphasised an
increasingly important distinction within longevity medicine: evidence of an
effect on a molecular pathway or biomarker is not necessarily evidence of
improved human healthspan or lifespan. Treacy advocated a clinical evidence
pathway progressing from biomarkers and biological-age measurements through
tissue function and healthspan, with lifespan representing the ultimate
endpoint.
The award reflects a broader evolution
within regenerative medicine. Techniques once considered primarily in the
context of aesthetic, reconstructive or wound-healing medicine are increasingly
being investigated in relation to cellular communication, senescence,
chronic inflammation, mitochondrial biology and the age-associated decline in
regenerative capacity.
Treacy has described this progression as a
move away from simply attempting to replace or repair damaged tissue towards
understanding the biological signals and tissue microenvironment that
determine whether effective regeneration can occur.
His work with PRP, stem-cell biology and
photobiomodulation over several decades has followed this principle: combining
biological signalling with attempts to create a cellular environment more
conducive to repair and regeneration.
The 2025 Cambridge award and the latest
recognition in New Delhi represent successive international acknowledgements of
this work and its progression from early regenerative therapies towards the
emerging interface between regenerative medicine and longevity science.
Professor Patrick Treacy, MB BCh, BSc (Hons), H.Dip Dermatology, MICGP, FACSAM (Hon), is a graduate of the Royal College of Surgeons in Ireland and holds a BSc (Hons) in Biochemistry from Queen’s University Belfast
.jpg)
.jpg)
Post Views : 6